SequelSEC

Polaryx Therapeutics, Inc. PLYX

Pharmaceutical Preparations · CIK 0002075320 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$7.82M
Fiscal year ended 2025-12-31
Free cash flow
Unavailable
Fiscal year ended 2025-12-31

Polaryx Therapeutics, Inc. (PLYX) reported net income of -$8.98M for the fiscal year ended 2025-12-31. This page shows 2 annual periods of income statement, balance sheet and cash flow figures normalized from Polaryx Therapeutics, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Polaryx Therapeutics, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
RevenueUnavailableUnavailable
Cost of revenueUnavailableUnavailable
Gross profitUnavailableUnavailable
Operating income-$7.82M-$4.35M
Net income-$8.98M-$30.36M
Research & development$6.27M$2.81M
Weighted-average diluted sharesshares 45.42Mshares 34.20M
Pretax income-$8.98M-$30.36M
Income tax expenseUnavailableUnavailable
Diluted EPS$-0.20$-0.89
Selling, general & administrativeUnavailableUnavailable
General & administrative$1.56M$1.54M
Selling & marketingUnavailableUnavailable

Balance

Polaryx Therapeutics, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Cash & equivalents$5.14M$4.62M
Total assets$5.17M$5.00M
Current assets$5.17M$5.00M
Total liabilities$605.00K$289.00K
Current liabilities$605.00K$289.00K
Total equity incl. NCI$4.56M$4.71M
Temporary (mezzanine) equityUnavailableUnavailable
InventoryUnavailableUnavailable
Accounts receivableUnavailableUnavailable
GoodwillUnavailableUnavailable
Long-term debtUnavailableUnavailable
Accounts payable$470.00K$72.00K

Cash flow

Polaryx Therapeutics, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Operating cash flow-$3.94M-$2.57M
Capital expendituresUnavailableUnavailable
Investing cash flowUnavailableUnavailable
Financing cash flow$4.47M$7.19M
Net change in cashUnavailableUnavailable
Stock-based compensation$4.72M$2.40M
Common dividends paidUnavailableUnavailable
Common share repurchasesUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailable

Derived

Polaryx Therapeutics, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-31
Free cash flowUnavailableUnavailable
Gross marginUnavailableUnavailable
Operating marginUnavailableUnavailable
FCF marginUnavailableUnavailable
SBC / revenueUnavailableUnavailable
Current ratio8.55x17.30x
Revenue YoY growthUnavailableUnavailable
Net marginUnavailableUnavailable
R&D / revenueUnavailableUnavailable
CapEx / revenueUnavailableUnavailable
Long-term debt / equityUnavailableUnavailable
Effective tax rateUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PLYX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-24View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.